+8.8%
DXCM vs MRNA
+511.3%
-502.5%
-32.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | -2.2% | +0.2% | -2.0% |
| 7D | -3.2% | +5.5% | -8.7% | -3.3% |
| 30D | +6.3% | +158.7% | -152.4% | +2.7% |
| 3M | +21.1% | +182.1% | -161.0% | +13.9% |
| 6M | +20.6% | +151.8% | -131.2% | +15.0% |
| YTD | +32.4% | +393.6% | -361.1% | +14.1% |
| 1Y | +8.8% | +499.5% | -490.6% | -9.8% |
| All | +8.8% | +511.3% | -502.5% | -9.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling